483 related articles for article (PubMed ID: 30383414)
21. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kage M; Aishima S; Kusano H; Yano H
J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
[TBL] [Abstract][Full Text] [Related]
22. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
Kleiner DE; Makhlouf HR
Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
24. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Loomba R; Friedman SL; Shulman GI
Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
27. [New aspects of nonalcoholic steatohepatitis].
Stefan N
Internist (Berl); 2019 Feb; 60(2):128-132. PubMed ID: 30645665
[TBL] [Abstract][Full Text] [Related]
28. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
29. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
[TBL] [Abstract][Full Text] [Related]
30. Concise review of lipidomics in nonalcoholic fatty liver disease.
Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
[TBL] [Abstract][Full Text] [Related]
31. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
32. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
Lai J; Wang HL; Zhang X; Wang H; Liu X
Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
[TBL] [Abstract][Full Text] [Related]
33. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Arab JP; Arrese M; Trauner M
Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
[TBL] [Abstract][Full Text] [Related]
34. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
35. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
Dornas W; Lagente V
Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
[TBL] [Abstract][Full Text] [Related]
36. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis.
Kurbatova IV; Topchieva LV; Dudanova OP; Shipovskaya AA
Ter Arkh; 2019 May; 91(4):21-27. PubMed ID: 31094472
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
39. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.
Hwang S; Yun H; Moon S; Cho YE; Gao B
Front Endocrinol (Lausanne); 2021; 12():751802. PubMed ID: 34707573
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
Mato JM; Alonso C; Noureddin M; Lu SC
World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
